Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)

Tang Hsiu Huang; Chin Wei Kuo; Chian Wei Chen; Yau Lin Tseng; Chao Liang Wu; Sheng Hsiang Lin

doi:10.1186/s12890-021-01559-7

Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)

研究成果: Comment/debate › 同行評審

摘要

Following publication of the original article [1], it was brought to our attention that panel ‘e’ was missing from Fig. 2; the figure has since been corrected in the published article. (Figure presented.).

原文	English
文章編號	193
期刊	BMC Pulmonary Medicine
卷	21
發行號	1
DOIs	https://doi.org/10.1186/s12890-021-01559-7
出版狀態	Published - 2021 12月

All Science Journal Classification (ASJC) codes

肺和呼吸系統醫學

存取文件

10.1186/s12890-021-01559-7

其它文件與鏈接

指紋

深入研究「Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)」主題。共同形成了獨特的指紋。

引用此

Huang, T. H., Kuo, C. W., Chen, C. W., Tseng, Y. L., Wu, C. L., & Lin, S. H. (2021). Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6). BMC Pulmonary Medicine, 21(1), 文章 193. https://doi.org/10.1186/s12890-021-01559-7

@article{81a0ee2a18af466e90dde54d1e032a21,

title = "Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)",

abstract = "Following publication of the original article [1], it was brought to our attention that panel {\textquoteleft}e{\textquoteright} was missing from Fig. 2; the figure has since been corrected in the published article. (Figure presented.).",

author = "Huang, \{Tang Hsiu\} and Kuo, \{Chin Wei\} and Chen, \{Chian Wei\} and Tseng, \{Yau Lin\} and Wu, \{Chao Liang\} and Lin, \{Sheng Hsiang\}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s12890-021-01559-7",

language = "English",

volume = "21",

journal = "BMC Pulmonary Medicine",

issn = "1471-2466",

publisher = "BioMed Central",

number = "1",

}

Huang, TH , Kuo, CW , Chen, CW , Tseng, YL , Wu, CL & Lin, SH 2021, 'Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)', BMC Pulmonary Medicine, 卷 21, 編號 1, 193. https://doi.org/10.1186/s12890-021-01559-7

Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6). / Huang, Tang Hsiu ; Kuo, Chin Wei ; Chen, Chian Wei 等.
於: BMC Pulmonary Medicine, 卷 21, 編號 1, 193, 12.2021.

研究成果: Comment/debate › 同行評審

TY - JOUR

T1 - Correction to

T2 - Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)

AU - Huang, Tang Hsiu

AU - Kuo, Chin Wei

AU - Chen, Chian Wei

AU - Tseng, Yau Lin

AU - Wu, Chao Liang

AU - Lin, Sheng Hsiang

PY - 2021/12

Y1 - 2021/12

N2 - Following publication of the original article [1], it was brought to our attention that panel ‘e’ was missing from Fig. 2; the figure has since been corrected in the published article. (Figure presented.).

AB - Following publication of the original article [1], it was brought to our attention that panel ‘e’ was missing from Fig. 2; the figure has since been corrected in the published article. (Figure presented.).

UR - https://www.scopus.com/pages/publications/85107580273

UR - https://www.scopus.com/pages/publications/85107580273#tab=citedBy

U2 - 10.1186/s12890-021-01559-7

DO - 10.1186/s12890-021-01559-7

M3 - Comment/debate

C2 - 34103038

AN - SCOPUS:85107580273

SN - 1471-2466

VL - 21

JO - BMC Pulmonary Medicine

JF - BMC Pulmonary Medicine

IS - 1

M1 - 193

ER -

Huang TH , Kuo CW , Chen CW , Tseng YL , Wu CL , Lin SH. Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6). BMC Pulmonary Medicine. 2021 12月;21(1):193. doi: 10.1186/s12890-021-01559-7